bid smashed, page-3

I hope that the next time we see financials they will show a reasonable and increasing royalty stream from Phosphagenic's Bodyshaper.

Now that Bodyshaper is on the shelves in Singapore, and with other Asian markets rolling out as I write, these royalties ought to be sufficient, along with cash assets, to fund the company for another four years. There is also the possibility that the royalty flow could come close to covering all ongoing corporate overheads within the next couple of years.

With no potential dilution on the horizon, and solid product commercialization prospects in the medium term, this stock ought to find its footing soon.